Any current/future new fundraising through debt or equity?

As of the current discussion, the management did not provide any specific guidance or plans regarding new fundraising through debt or equity. They mentioned no comments on any upcoming fundraising activities or different amounts for the future. If there is any development related to fundraising, the company stated they will surely update stakeholders. The company is currently utilizing cash through shareholder rewards (buyback/dividend) and CAPEX investments (notably 70-80 crores for ophthalmic line expansion). No explicit plans for raising debt or equity were indicated in the Q&A session on p

Any current/future capex/capital investment/strategic investment?

The company is investing about ₹70 to ₹80 crores in expanding and upgrading its ophthalmic manufacturing line at the Waluj plant. This CAPEX is partly for replacement and upgradation purposes. No specific guidance or numbers have been shared yet regarding returns or asset turns from this ophthalmic CAPEX; management may provide updates later. Other than ophthalmic CAPEX, the company focuses on rewarding shareholders via buybacks or dividends using surplus cash (around ₹750 crores as of June). There is no indicated major strategic investment or acquisition disclosed currently; the compa

Future growth expectations in sales/revenue/volumes?

Overall growth outlook is positive with an 11% revenue increase and 7.5% volume growth reported. Top three products—Enerzal, Electral, and Zifi—show robust growth: Zifi up 11%, Electral 32%, and Enerzal 22% in recent quarters. Plans are aggressive but cautious due to secondary market and external factors like COVID impact. Growth expected to continue driven by focus on top 10 brands, expansion of product divisions, and new market penetrations. Export market performing well; US exports increased by ₹7 crores year-over-year. Marketing and sales efforts are being intensified with increased Medica

Future growth expectations in earnings/operating earnings/profits/EPS?

The company plans to continue an aggressive growth strategy, focusing on execution and market trends to sustain momentum. Growth drivers include key products like Enerzal, Electral, and Zifi, which showed volume growth of 22%, 32%, and 11% respectively in recent quarters. The management is optimistic about outperforming the Indian Pharmaceutical Market (IPM) if market conditions remain stable. Gross margins are expected to improve in upcoming quarters due to price hikes reflecting fully in inventory, though raw material and packaging costs remain a factor to watch. Operating expenses, particul

FDCQ1 FY23Pharmaceuticals & Biotechnology

FDC Q1 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹372.1P/E: 18.4Market Cap: ₹6.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Overall growth outlook is positive with an 11% revenue increase and 7.5% volume growth reported.
Top three products—Enerzal, Electral, and Zifi—show robust growth: Zifi up 11%, Electral 32%, and Enerzal 22% in recent quarters.
Plans are aggressive but cautious due to secondary market and external factors like COVID impact.
Growth expected to continue driven by focus on top 10 brands, expansion of product divisions, and new market penetrations.
Export market performing well; US exports increased by ₹7 crores year-over-year.
Marketing and sales efforts are being intensified with increased Medical Representative headcount.
Price hikes taken recently expected to positively impact margins and revenue.
Some quarter-to-quarter expense fluctuations due to promotional spend accounting; expect stabilization over the year.
Management optimistic about maintaining mid-teens growth rates going forward excluding one-off COVID impacts.

Margin guidance

Category 3

The company plans to continue an aggressive growth strategy, focusing on execution and market trends to sustain momentum.
Growth drivers include key products like Enerzal, Electral, and Zifi, which showed volume growth of 22%, 32%, and 11% respectively in recent quarters.
The management is optimistic about outperforming the Indian Pharmaceutical Market (IPM) if market conditions remain stable.
Gross margins are expected to improve in upcoming quarters due to price hikes reflecting fully in inventory, though raw material and packaging costs remain a factor to watch.
Operating expenses, particularly sales and marketing costs, have increased but are expected to normalize or stabilize over the year.
Export business growth is targeted, especially in the US market, to contribute more significantly to overall revenues.
Overall revenue growth guidance is around 10-15% excluding one-off COVID-related items, with potential for sustained mid-to-high teens growth in the domestic business driven by multiple brands.

See what FDC management said on margin guidance — free account, 30 seconds.

Fundraise plans

As of the current discussion, the management did not provide any specific guidance or plans regarding new fundraising through debt or equity.
They mentioned no comments on any upcoming fundraising activities or different amounts for the future.
If there is any development related to fundraising, the company stated they will surely update stakeholders.
The company is currently utilizing cash through shareholder rewards (buyback/dividend) and CAPEX investments (notably 70-80 crores for ophthalmic line expansion).
No explicit plans for raising debt or equity were indicated in the Q&A session on pages 5, 17, and 18.

Order book

The provided transcript from the document "1000.pdf" does not contain any specific information or discussion related to the current or expected order book or pending orders of the company. The Q&A and management commentary largely focused on topics such as: - CAPEX on ophthalmic assets and related asset turns - Impact of online platforms on sales - Growth and volume contributions of key products like Enerzal, Electral, and Zifi - Marketing spend and promotional costs - Gross margin pressure due to inflation in raw materials and packaging - Export business and its margin profile - Use of cash including buyback and CAPEX plans No clear details or figures about order books or pending orders were mentioned on the analyzed pages. If you need insights on order book status, you might need to refer to other sections or documents.

See what FDC management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is investing about ₹70 to ₹80 crores in expanding and upgrading its ophthalmic manufacturing line at the Waluj plant.
This CAPEX is partly for replacement and upgradation purposes.
No specific guidance or numbers have been shared yet regarding returns or asset turns from this ophthalmic CAPEX; management may provide updates later.
Other than ophthalmic CAPEX, the company focuses on rewarding shareholders via buybacks or dividends using surplus cash (around ₹750 crores as of June).
There is no indicated major strategic investment or acquisition disclosed currently; the company is consolidating its core brands and expanding existing business lines.
Export business is an area where the company plans to continue investment to increase sales, ensuring risks are managed.
Promotion and marketing costs have increased, partly due to new divisions and launching focused marketing on top products, but no large new launches recently.

Track FDC — get its next earnings analysis in your feed

How does FDC rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisFDC

Rev 3Mar 3

See where FDC sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does FDC rank in Pharmaceuticals & Biotechnology?

Compare FDC against every Pharmaceuticals & Biotechnology company (Q1 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What FDC's management said in earlier quarters

Earlier calls (6)

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

FDC Q1 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does FDC rank in Pharmaceuticals & Biotechnology?

Continue your research

What FDC's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season